statistiche ricercatore

Continente	#
NA - Nord America	917
EU - Europa	540
AS - Asia	463
SA - Sud America	78
AF - Africa	15
Continente sconosciuto - Info sul continente non disponibili	2
Totale	2.015

Nazione	#
US - Stati Uniti d'America	892
PL - Polonia	166
SG - Singapore	156
CN - Cina	150
IT - Italia	97
BR - Brasile	65
UA - Ucraina	63
DE - Germania	51
HK - Hong Kong	40
FI - Finlandia	38
VN - Vietnam	30
GB - Regno Unito	25
BD - Bangladesh	24
FR - Francia	18
IN - India	17
BE - Belgio	16
IE - Irlanda	16
TR - Turchia	15
CA - Canada	13
CZ - Repubblica Ceca	10
RU - Federazione Russa	8
ZA - Sudafrica	8
MX - Messico	7
NL - Olanda	7
AR - Argentina	6
ID - Indonesia	6
IQ - Iraq	5
JP - Giappone	5
AT - Austria	4
NO - Norvegia	4
ES - Italia	3
GR - Grecia	3
IL - Israele	3
JM - Giamaica	3
SE - Svezia	3
VE - Venezuela	3
CH - Svizzera	2
CO - Colombia	2
DZ - Algeria	2
EC - Ecuador	2
EU - Europa	2
KR - Corea	2
MA - Marocco	2
AE - Emirati Arabi Uniti	1
AM - Armenia	1
AZ - Azerbaigian	1
BA - Bosnia-Erzegovina	1
DO - Repubblica Dominicana	1
ET - Etiopia	1
HN - Honduras	1
KE - Kenya	1
KG - Kirghizistan	1
KZ - Kazakistan	1
LA - Repubblica Popolare Democratica del Laos	1
LT - Lituania	1
LV - Lettonia	1
MD - Moldavia	1
OM - Oman	1
PH - Filippine	1
PK - Pakistan	1
PT - Portogallo	1
RO - Romania	1
SA - Arabia Saudita	1
SN - Senegal	1
Totale	2.015

Nome	#
Speeding Up the Identification of Cystic Fibrosis Transmembrane Conductance Regulator-Targeted Drugs: An Approach Based on Bioinformatics Strategies and Surface Plasmon Resonance	284
High sulfation and a high molecular weight are important for anti-hepcidin activity of heparin	202
Natural Histogel-Based Bio-Scaffolds for Sustaining Angiogenesis in Beige Adipose Tissue	197
A novel pro-oncogenic mutated form of VEGFR2 modulates the activity of co-expressed wild-type receptor in melanoma	194
Oversulfated heparins with low anticoagulant activity are strong and fast inhibitors of hepcidin expression in vitro and in vivo	193
A novel VEGFR2 mutation has oncogenic potential in BRAF wild type melanoma	164
A novel variant of VEGFR2 identified by a pan-cancer screening of recurrent somatic mutations in the catalytic domain of tyrosine kinase receptors enhances tumor growth and metastasis	163
Evaluation of Paracellular Permeability in VEGFR2 Mutants Patient-Derived Organoid	148
A novel VEGFR2 mutation has oncogenic potential in BRAF wild-type melanoma	138
Role of VEGFs in metabolic disorders	137
VEGFR2 activation mediates the pro-angiogenic activity of BMP4	130
Identification and characterization of pro-oncogenic low frequency VEGFR2 mutations	105
Totale	2.055

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	17	0	0	0	0	0	0	0	0	0	0	0	17
2021/2022	116	9	17	1	8	3	7	5	7	4	19	11	25
2022/2023	90	13	6	4	5	6	25	0	5	17	0	3	6
2023/2024	148	10	4	14	18	6	27	7	19	23	3	1	16
2024/2025	324	11	4	3	56	22	18	21	17	33	19	66	54
2025/2026	603	62	47	47	80	72	35	96	11	31	64	55	3
Totale													2.055